/PRNewswire/ A new survey commissioned by Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and conducted by public opinion research firm.
Nevro criticizes Medtronic's use of older study to support recent FDA approval of spinal cord stimulation therapy for treating painful diabetic neuropathy.